TScan Therapeutics announces $30M registered direct offering

TScan Therapeutics (TCRX) entered into a securities purchase agreement with Lynx1 Capital Management and an investment fund advised by Lynx1 for the sale of approximately $30M of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per share, representing a premium of 37% to the last closing price of TScan Therapeutics’ common stock, and a 34% premium over the 10-day volume weighted average closing price. The financing is expected to close on or about December 27, 2024, subject to customary closing conditions.